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Abstract
Purpose To investigate the changes in choroidal
thickness (ChT) following panretinal photocoagula-
tion (PRP) for diabetic retinopathy (DR) and compare
ChT in relation to DR severity.
Methods Thirty-two eyes [19 eyes with proliferative
DR (PDR) and 13 eyes with severe nonproliferative
DR (NPDR)] for which PRP was necessary were
analyzed. ChT was measured before PRP and at 1, 3,
and 6 months after PRP using the swept-source optical
coherence tomography. ChT of the 61 eyes matched
with the PDR patients for the mean age and axial
length was also measured and statistically compared in
relation to severity.
Results The central field ChT before PRP treatment
was 268.6 ± 104.5 lm (mean ± standard deviation)
and was significantly decreased at 1, 3, and 6 months
after PRP (254.5 ± 105.3, 254.2 ± 108.2, and
248.1 ± 101.8 lm, respectively, P\ 0.0001). The
central field ChT of severe NPDR (323.2 ± 61.3 lm)
was significantly thicker than that of normal
(248.3 ± 70.7 lm) and mild to moderate NPDR
(230.0 ± 70.3 lm, P = 0.0455 and 0.0099, respec-
tively). Moreover, the central field ChT of PDR
(307.3 ± 84.1 lm) was significantly thicker than of
mild to moderate NPDR (P = 0.0169).
Conclusion ChT significantly decreased after PRP,
which continued for at least 6 months after treatment.
ChT of severe NPDR and PDR was significantly
thicker than that of mild to moderate NPDR. ChT of
patients with DR was changed according to the
treatment and severity of DR.
Keywords Diabetic retinopathy  Panretinal
photocoagulation  Choroidal thickness  Swept-
source optical coherence tomography
Introduction
Diabetic retinopathy (DR) is still a leading cause of
blindness in working populations in both developing
or advanced countries [1]. Panretinal photocoagula-
tion (PRP) is an established treatment for this serious
ocular disease [2], and it has been performed on
patients with both severe nonproliferative DR (NPDR)
and proliferative DR (PDR) [3]. Diabetes mellitus is a
disease that affects the retina and can also cause
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systemic microcirculatory disorders. When such
microvascular complications progress, the risk of
developing macroangiopathy also increases [4, 5]. In
particular, diabetes impairs the ocular circulation by
causing changes in the retinal blood vessels and likely
affects choroidal blood flow. There are many unknown
factors regarding the effects of DR on choroid and the
mechanisms by which PRP changes the choroid.
Since Spaide et al. [6] reported a noninvasive
evaluation of choroidal thickness (ChT) in normal
volunteers using enhanced depth imaging optical
coherence tomography (EDI-OCT) in 2008, several
studies on ChT have been reported using EDI method
[7–13]. As for ChT in patients with DR, Regatieri and
Unsal [7, 8] reported that ChT in patients with diabetic
macula edema and PRP-treated PDRwere thinner than
in normal subjects. In addition, Kim et al. [9] reported
that ChT in patients with PDR was significantly
increased compared with patients with mild or mod-
erate NPDR, whereas ChT in PRP-treated eyes was
thinner.
Several studies [10–13] have reported longitudinal
changes in ChT before and after the PRP procedure;
however, the results of the studies are still controver-
sial; ChT was found to be increased [10, 11],
decreased [12], or increased then decreased [13].
However, measuring ChT in fovea by the pinpoint
measurement in EDI is likely influenced by the
increase or decrease in the regional ChT as well as
the irregularity of the choroidoscleral border [14].
Additionally, measurement of retinal thickness of the
central subfield around the fovea provided better
reproducibility than did the measurement of the center
point [15]. Thus, a 3D volumetric raster scan by swept-
source optical coherence tomography (SS-OCT) is
considered to be a superior method for measuring the
ChT.
The first aim of the study was to clarify the
longitudinal ChT changes in PRP-treated eyes. The
second aim was to compare ChT among patients with
DR as well as normal subjects using SS-OCT.
Methods
Patients
Patients with severe NPDR or PDR for whom PRPwas
considered necessary and performed between August
2014 and March 2015 were enrolled in this study. A
total of 70 eyes of 40 patients with severe NPDR and
56 eyes of 36 patients with PDR were enrolled for this
study. To compare the severity of DR and ChT,
healthy subjects and diabetic patients without DR
(noDR), mild to moderate NPDR (m–m NPDR), and
severe NPDR and PDR without PRP were enrolled.
This study was approved by the Institutional Review
Board of Saneikai Tsukazaki Hospital and performed
in accordance with the Declaration of Helsinki.
Written, informed consent to participate in the study
was obtained from all participants. All patients
underwent an eye examination including best-cor-
rected visual acuity, slit lamp microscopy, and fundus
photography (Optos 200Tx, Optos Inc., Scotland,
UK). Visual acuity was presented in logMAR, and the
axial length was also measured using IOL Master
(Carl Zeiss Meditec, Jena, Germany). Fluorescein
angiography (FA) was performed to accurately deter-
mine the severity in severe NPDR and PDR eyes. The
severity of the retinopathy was based on the classifi-
cation proposed by the Global Diabetic Retinopathy
Project Group [16].
Eyes with a retinal disease other than DR, glau-
coma, ocular trauma, history of uveitis, and turbid
ocular media that can obscure the border of the choroid
in optical coherence tomography (OCT) were
excluded. Eyes that had undergone cataract surgery
in the last 12 months were also excluded. For eyes
with DR, only treatment-naive eyes were included,
and those with a history of photocoagulation, vitreous
injection of anti-VEGF drugs, and vitreous surgery
were excluded. Eyes treated with PRP using a pattern
scan laser were excluded.
The right eye was enrolled in the study; if the right
eye met any of the exclusion criteria, the left eye was
enrolled. For bilaterally PRP-treated eyes with differ-
ent severity, each eye was enrolled according to its
severity.
Treatment protocol
PRP was performed over four sessions every other
week. The procedure was carried out in the following
order: (1) superior; (2) nasal; (3) inferior; and (4)
temporal. The spot size was set at 200–250 lmwith an
exposure duration of 0.2–0.3 s. A panfundus contact
lens (Ocular Mainster PRP 165, Ocular, Bellevue,
WA, USA) was worn, and the total number of
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exposures was between 900 and 1900. The multicolor
photocoagulation laser device (NOVUS Varia, Lume-
nis, UT, USA) with a wavelength of 532 (green) or 561
(yellow) nm was used. According to the ETDRS
protocol [17], the laser power was adjusted to induce
gray–white spots.
For eyes that had fovea-involving macular edema
before the PRP treatment, or when macular edema was
found during treatment, 20-mg sub-Tenon injection of
triamcinolone acetonide (STTA) was administered.
The decision to treat with STTA was made at the
discretion of an experienced ophthalmologist.
Swept-source optical coherence tomography
The macular area (6 9 6 mm) was measured using
SS-OCT (DR1 OCT-1; Topcon, Tokyo, Japan). The
SS-OCT system is a swept-source laser device that can
provide a scanning speed of 100,000 A-scans per
second with a tuning range of approximately 100 nm
centered at the 1-lm wavelength region with an
imaging depth of 2.6 mm. The SS-OCTmeasurements
were performed by trained examiners after inducing
pupil dilation. Using a 3D volumetric raster scan
protocol, 3D volumetric data were obtained in 0.8 s,
and each 3D scan covered a 6 9 6 mm area centered
on the fovea with 512 A-scans 9 256 B-scans. To
improve the quality of the images, four consecutive
B-scan images of the same area were averaged [14].
Measurements of choroidal thickness
All patients who scheduled for PRP treatment under-
went SS-OCT examinations before and after each
session at 1, 3, and 6 months after PRP. Additionally,
the patients underwent the SS-OCT examination at the
time of the initial visit or at the regular visit and their
DR severity and ChT were compared. With a set of 64
B-scan images obtained by averaging each of the four
consecutive B-scans, a ChT map was created using
semiautomatic segmentation. ChT was measured as
the distance between the outer border of the retinal
pigment epithelium and the inner surface of the
choroidal-scleral border. However, semiautomatic
segmentation does not always accurately detect the
choroidal-scleral border. Therefore, all 64 B-scan
images were manually corrected by certified experi-
enced orthoptists using built-in software. The inter-
observer reproducibility of the ChT measurements
obtained by this manual segmentation has previously
been reported by our team [14], and the intraclass
correlation coefficient (ICC) of the ChT measure-
ments by two observers was extremely favorable
(between 0.990 and 0.999).
ChT is automatically divided into sections of the
ETDRS map, and the mean ChT of each section is
automatically calculated and presented by the soft-
ware. The inner and outer rings are 3 and 6 mm in
diameter, respectively, and each ring is divided into
four parts. The mean central field choroidal thickness
(CFChT) was defined as the mean ChT of the center
area spanning a 1 mm diameter on the ETDRS map
(Fig. 1A).
In addition, to obtain the subfoveal choroidal
thickness (SFChT) using the same point measure-
ments as the EDI method from the scan images
obtained to measure CFChT, the subfovea was man-
ually marked on the images that went through the
subfovea. Subsequently, the distance between the
outer retinal pigment epithelium border and the inner
surface of the choroidal-scleral border was automat-
ically calculated and statistically compared (Fig. 1B).
Statistical analyses
The statistical analyses were performed using JMP
version 10.0 software package (SAS Institute Inc.,
Cary, NC, USA). A comparison of the duration of DR
was performed using a one-way analysis of variance
(ANOVA) followed by a Tukey’s HSD test. A
comparison of ChT at each time point was performed
first by repeated measures one-way ANOVA, and a
comparison between groups was performed by
Tukey’s HSD test. Additionally, a two-way repeated
measures ANOVA was used to compare between
STTA-treated and untreated eyes. A P value of less
than 0.05 was considered statistically significant.
Results
The characteristics of the PRP-treated patients are
presented in Table 1. Ninety-four eyes of 53 patients
were excluded as they did not meet the inclusion
criteria. Finally, 32 eyes from 23 subjects (6 females
and 17 males) completed the study and data were
subsequently analyzed.
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The mean age (SD) of the PRP patients was 55.6
(±12.8) years (range: 37–79 years). The mean axial
length (SD) was 23.6 (±0.98) mm (range:
21.7–26.0 mm), and the mean known disease duration
of diabetes mellitus (SD) was 13.5 (±11.8) years
(range: 1–43 years). Based on the international clas-
sification of DR, 19 eyes were considered PDR and 13
eyes were severe NPDR. The mean (SD) logMAR
visual acuity at baseline was 0.06 (±0.19) (range:
-0.18 to 0.52), and the logMAR visual acuity at
6 months was 0.09 (±0.23) (range: -0.18 to 0.82).
Longitudinal ChT changes in PRP
CFChT before treatment was 268.6 ± 104.3 lm and
at 1, 3, and 6 months was 254.5 ± 105.3,
254.2 ± 108.2, and 248.1 ± 101.8 lm, respectively.
The result of the repeated measures one-way ANOVA
was P\ 0.0001, and the group comparison using a
Tukey’s HSD test showed that the mean CFChT was
significantly decreased at all post-treatment time
points compared with the pretreatment value (all
P\ 0.005) (Fig. 2).
Fig. 1 Choroidal thickness (ChT) measurements using SS-
OCT. A The mean central field choroidal thickness (CFChT)
was defined as the mean ChT of the center area spanning a 1 mm
diameter on the ETDRS map (white arrow). B The subfoveal
choroidal thickness (SFChT), which is the distance between the
outer RPE border and the inner surface of the choroidal–scleral
border, was automatically calculated on the images that went
through the subfovea (white arrowhead)
Table 1 Patient
demographics in panretinal
photocoagulation study
Values are shown as mean
(SD)
Visual acuity; mean
logMAR visual acuity
Number of patients (sex) 23 (6 females, 17 males)
Number of eyes 32
Age (years) 55.9 (12.8) (range: 37–79)
Number of eyes by severity level PDR, 19; severe NPDR, 13
Visual acuity at baseline 0.06 (0.19)
Visual acuity at 6 months 0.09 (0.23)
Axial length, mm 23.6 (0.98)
Mean known disease duration 12.8 (11.5) (range: 1–42)
HbA1c (%) 8.1 (2.1)
Fig. 2 Changes in the central field choroidal thickness
(CFChT) after panretinal photocoagulation (PRP). The mean
CFChT after PRP at 1, 3, and 6 months was clearly decreased
compared with the baseline values. Asterisk indicates the
significant difference between the measurements points by
Tukey’s HSD (P\ 0.005). Error bars represent standard error
of the mean
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Multiple comparisons tests showed no significant
difference between 1 and 3 months and between 3 and
6 months (P = 0.9998 and 0.1392, respectively).
Moreover, six eyes received STTA during the study
period. No statistically significant difference was
found for the mean CFChT between the STTA-treated
eyes (N = 6) and eyes without STTA treatment
(N = 26) (multivariate ANOVA, P = 0.7921).
SFChT was 268.4 ± 102.9 lm before treatment
and 253.4 ± 103.1, 253.8 ± 107.1, and
252.9 ± 110.5 lm at 1, 3, and 6 months after treat-
ment, respectively. The results of the repeated mea-
sures one-way ANOVA were P = 0.0002, and the
group comparison using the Tukey’s HSD test showed
that the mean SFChT was significantly decreased at all
post-treatment time points compared with the pre-
treatment value (all P\ 0.005) (Fig. 3).
Multiple comparisons tests showed no significant
difference between 1 and 3 months and between 3 and
6 months (P = 0.9998 and 0.9532, respectively).
Comparison of ChT among the different groups
of DR severity and normal subjects
Table 2 shows the characteristics of the patients
included in the comparison of ChT with severity of
DR. The mean CFChT of the eyes for each severity
matched for the mean age and axial length with the
untreated PDR patients was as follows: normal,
248.3 ± 70.7; noDR, 250.2 ± 55.4; m–m NPDR,
230.0 ± 70.3; severe NPDR, 323.2 ± 61.3; and
PDR, 307.3 ± 84.1.
ChT of the PDR group was significantly thicker
than that of the m–m NPDR group. Moreover, CFChT
of the severe NPDR group was significantly thicker
than that of the normal and m–m NPDR groups
(P\ 0.005) (Fig. 4).
The mean SFChT of the eyes for each severity
group was as follows: normal, 243 ± 71.4; noDR,
251.3 ± 61.9; m–m NPDR, 227.1 ± 71.3; severe
NPDR, 323.1 ± 66.0; and PDR, 301.7 ± 80.8. In
addition, SFChT of the PDR group was significantly
thicker than that of the m–m NPDR group; SFChT of
the severe NPDR group was significantly thicker than
that of the normal and m–m NPDR groups (Fig. 5).
The results of CFChT and SFChT were extremely
similar.
Discussion
In the current study, we confirmed that PRP treatment
causes a decrease in ChT, which continues for up to
6 months. As photocoagulation scarring becomes
enlarged over time [18], changes in ChT are also
likely to continue over a long period. The choroid
consists of abundant vascular components and may be
greatly influenced by changes in its blood flow. Our
observation period of 6 months is appropriate because
ocular blood flow velocities are stable from 6 months
to 2 years following PRP [19].
According to the early longitudinal studies on ChT
after PRP [10–13], SFChT increased after 1 week
[10, 13]. Cho et al. [10] speculated that increases in
ChT are due to increased blood flow due to vasodi-
lation or choroidal effusion induced by the laser,
which damages the peripheral choriocapillaris, con-
sequently decreasing the peripheral choroidal blood
flow. As a result, redistribution of blood flow occurs,
and the choroidal blood flowing around the foveal
centralia increases, resulting in an increase in SFChT.
However, in the present study, ChT at 1 week after
PRP was not measured and thus cannot be directly
compared.
Meanwhile, some reports showed that SFChT was
decreased at 1 month [12, 13] and 3 months after PRP
[13], which suggested that ChT tends to decrease over
time. Considering these findings together with the data
from our present study, although ChT may increase in
the short term, it tends to decrease over the long term.
Fig. 3 Changes in the subfoveal choroidal thickness (SFChT)
after panretinal photocoagulation (PRP). The mean SFChT after
PRP at 1, 3, and 6 months was clearly decreased compared with
the baseline values. Asterisk indicates the significant difference
between the measurements points by Tukey’s HSD (P\ 0.005).
Error bars represent standard error of the mean
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Zhang et al. [13] presented three hypotheses
regarding the observed decreases in ChT: (1) thermal
damage by photocoagulation spreads to the choroid
which consequently interferes with choroidal
reperfusion or reorganization, and results in a reduc-
tion in ChT; (2) PRP damages the RPE and decreases
VEGF secretion which results in decreased dilation
and permeability of the choroidal vessels; (3) the outer
retina is destroyed and the hypoxic inner retina comes
closer to the highly saturated choriocapillaris, which
then improves the hypoxic state. Autoregulation
decreases the choroidal blood flow and causes a
decrease in ChT.
However, Zhu et al. [11] reported a significant
increase in SFChT at 1 and 3 months after PRP,
revealing completely different results from other
studies. They argued [11] that a thinner ChT around
the photocoagulated area causes a reduction in the
peripheral choroidal blood flow, resulting in a redis-
tribution of blood supply to the fovea that conse-
quently increases SFChT. In our study as well as
others, a conventional laser was used to perform PRP.
In contrast, Zhu et al. [11] used a pattern scan laser
PRP. It has been reported that the laser scarring from a
pattern scan laser reduces rather than expands in size,
and the reduction can be up to 35% [20]. In addition, a
study which histopathologically compared the scars by
both a conventional and pattern scan laser reported
that conventional laser scar lesions exhibited both
outer and inner nuclear layer loss. In contrast, pattern
scan laser scar lesions exhibited only outer nuclear
layer loss, and the inner nuclear layer was preserved
[21]. This difference may have contributed to the
inconsistent results between these studies.
Previous studies have reported that ChT negatively
correlates with age and axial length [22, 23]. There-
fore, in this study, the mean CFChT was statistically
compared with the data matched with PDR patients for
age and axial length. The results indicate that the mean
ChT of the severe NPDR and PDR groups was
significantly thicker than that of the m–m NPDR
group. Moreover, the mean ChT of the severe NPDR
Table 2 Characteristics of normal subjects and patients with diabetes mellitus by severity
Normal noDR m–m NPDR Severe NPDR PDR
Number 20 14 16 11 18
Sex (female) 8 (12) 9 (5) 11 (5) 6 (5) 12 (6)
Age (years) 50.6 (9.4) 50.7 (7.1) 50.6 (7.7) 50.7 (5.7) 50.6 (9.9)
Axial length (mm) 23.8 (0.7) 23.8 (1.2) 23.7 (1.2) 23.6 (1.1) 23.7 (0.9)
Values are shown as mean (SD)
Fig. 4 Comparisons of choroidal thickness (ChT) among DR
severity groups and normal subjects. Asterisk indicates statis-
tically significant pair by Tukey’s HSD test (P\ 0.005)
Fig. 5 Comparisons of SFChT among DR severity groups and
normal subjects. Asterisk indicates statistically significant pair
by Tukey’s HSD test (P\ 0.005)
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group was also significantly thicker than that of the
normal group. These findings illustrate that as the
severity worsens, ChT also increases. These findings
are supported by Kim et al. [9], who found that ChT
significantly increased as the severity worsened from
mild/moderate NPDR to PDR. We suspected that the
same point measurements as EDI-OCT might be
easily affected by the local increase or decrease in
ChT, as well as the irregularity of the choroidoscleral
border; however, the values were almost identical to
the mean values obtained within the 1-mm center area
(CFChT). As the choroid is thickest at the fovea
centralis in DR [7–9], this seems to be the reason why
there was no difference observed between CFChT and
SFChT.
Increases in ChT as the severity of retinopathy
worsens are likely caused by an increase in vascular
endothelial growth factor (VEGF). DR causes retinal
nonperfusion, and VEGF is produced. VEGF is
induced by hypoxia and results in elevated intraocular
VEGF levels [24–26]. One study found that ChT was
thinner when patients were treated with a combination
of laser treatment and anti-VEGF therapy than when
they were treated with laser treatment alone [27]. Such
findings suggest that VEGF causes the choroid to
thicken.
As ChT tends to increase the severity of DR and
PRP significantly decreases ChT, a positive correla-
tion between ChT and DR activity or intraocular
VEGF level may exist. Based on this assumption, the
decrease in ChT following PRP and the continued
decrease for at least 6 months observed in this study
may be associated with a decline in the retinopathy
symptoms. Therefore, ChT may be a useful indicator
for controlling the progression of DR.
Due to the small sample size of our study, the
possibility of biased results cannot be ruled out. The
reliability of our results should be further validated
by studying a larger number of cases. In our study,
there were no statistical differences in ChT between
the STTA-treated eyes and those that did not receive
treatment; however, there was a study which
reported a decrease in ChT in DME eyes following
intravitreal triamcinolone acetonide [28]. Thus, this
may have influenced our study results. Additionally,
having a longer follow-up period may help to clarify
the relationship between ChT and severity of
retinopathy.
Conclusion
ChT significantly decreased following PRP, and the
decline continued for at least 6 months after treatment.
ChT of patients with severe NPDR and PDR was
significantly thicker than that with m–m NPDR
patients. ChT of patients with DR changed according
to the treatment and severity of DR.
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